Raydiax, a Germany-based medical technology company, has raised €7.5 million in Series A1 funding to advance clinical studies and prepare the market launch of its therapy assistance CT scanner, TACT. The company, a spin-off from the STIMULATE research campus at Otto von Guericke University Magdeburg, is developing imaging technology designed to support minimally invasive cancer therapies directly within operating rooms.
The funding round includes €5 million in venture capital from existing business angels, bmp Ventures through the IBG funds, and the GETEC Family Office of Dr. Karl Gerhold. In addition, the company received €2.5 million from the European Commission through the EIC Accelerator program, a funding initiative aimed at supporting high-potential deep-tech innovations across Europe.
Raydiax plans to use the capital to initiate first-in-human studies of its TACT system while continuing development toward production readiness. The company will also expand its organizational capabilities across sales, manufacturing, and quality management as it prepares for initial commercial installations.
The TACT system is designed to support therapy planning, execution, and monitoring within a single integrated imaging platform tailored for interventional oncology procedures. Unlike conventional CT scanners typically used in radiology departments for diagnostic imaging, the Raydiax system is intended for use directly in operating rooms to assist physicians during minimally invasive treatments.
Minimally invasive cancer therapies are increasingly viewed as a way to reduce complications, shorten procedure times, and enable faster patient recovery compared with traditional surgical approaches. By enabling real-time imaging during procedures, Raydiax aims to expand the range of treatments that can be performed using these techniques.
The company was founded in 2022 and is headquartered in Magdeburg’s Science Harbor. Its founding team emerged from the STIMULATE research campus, a collaborative initiative focused on developing technologies for image-guided minimally invasive medicine.
The new financing will support Raydiax as it advances clinical validation of the TACT system and moves toward regulatory approval and broader commercialization.
KEY QUOTES
“With the successful closing of our Series A1, we have reached a decisive milestone on our path toward clinical application. Following the successful seed phase and the development of our preclinical prototype, we are now focusing on generating early clinical evidence as part of the planned first-in-human studies. At the same time, we are establishing the organizational foundations for market entry. The continued trust of our existing investors, along with the support of new strategic partners, confirms the technological maturity and market potential of our approach.”
Dr. Thomas Hoffmann, CEO And Co-Founder Of Raydiax
“As the GETEC Group, we are pleased to invest in innovative technologies at our locations. After investing in new technological approaches in the field of magnetic resonance imaging through Neoscan Solutions, we became aware of RAYDIAX in the CT sector. With its innovative technology, RAYDIAX enables focused live CT imaging that reduces radiation exposure for both patients and physicians, as well as procedure time in the operating room. In addition to increasing efficiency in medical processes, RAYDIAX has also made a larger CT gantry opening possible, which will enable new surgical methods in the future, such as the use of robotics. Altogether, this convinced us.”
Steffen Schmidt, CFO Of The GETEC Group
“As an engineer, I am particularly interested in complex technical systems. The strong scientific foundation and the outstanding technical expertise of the founding team convinced me. The TACT system fills a functional gap in operating room workflows – specifically in interventional radiology.”
Klemens Gutmann, Founder Of Regiocom And Business Angel
“With the successful closing of the Series A1, RAYDIAX reaches a decisive turning point from technology development to clinical application and market entry. TACT addresses a clearly defined clinical need in interventional oncology and has the potential to establish a new device category for minimally invasive cancer therapies. We see RAYDIAX as being exceptionally well positioned to establish an international presence in this growing market segment.”
Dr. Jan Alberti, Managing Partner At bmp Ventures
“RAYDIAX is developing a technology with the potential to significantly improve the care of cancer patients. We are proud to see the strong progress the team has made since our seed investment – culminating in the recently closed Series A1 and the prestigious EIC Accelerator grant. Since the early stages, Thomas and his team have consistently taken the right steps toward achieving clinical relevance, and we look forward to continuing to support them closely on their journey.”
Dr. Jan Engels, Senior Investment Manager At High-Tech Gründerfonds
“The EIC Accelerator is one of the most selective funding programs for deep-tech innovation in Europe. That RAYDIAX has successfully passed this highly competitive process and closed its Series A1 financing round is an outstanding achievement. It confirms the scientific excellence, the technological and clinical differentiation of the TACT system, as well as the entrepreneurial maturity of the team. For the STIMULATE Research Campus at Otto von Guericke University Magdeburg, this sends a strong signal: long-term medical technology research conducted here is giving rise to internationally competitive high-tech companies with clinical and economic relevance.”
Prof. Dr. rer. nat. Georg Rose, Chairman Of The Board Of The STIMULATE Research Campus
